Evidence map›Paper›PMID 26225756›Full record

ArticlePloS one2015

Monitoring the Activation of the DNA Damage Response Pathway in a 3D Spheroid Model.

Odile Mondesert, Céline Frongia, Olivia Clayton, Marie-Laure Boizeau, Valérie Lobjois, Bernard Ducommun

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Quantifying single-cell responses to irradiation in 3D.Frontiers in bioengineering and biotechnology · 2026
    Article
  2. Expert reviews in molecular medicine · 2022
    Review
  3. Article
  4. Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids.Journal of experimental & clinical cancer research : CR · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Odile MondesertUniversité de Toulouse; ITAV-USR3505, F-31106 Toulouse, France; CNRS; ITAV-USR3505, F-31106 Toulouse, France.
Céline FrongiaUniversité de Toulouse; ITAV-USR3505, F-31106 Toulouse, France; CNRS; ITAV-USR3505, F-31106 Toulouse, France.
Olivia ClaytonUniversité de Toulouse; ITAV-USR3505, F-31106 Toulouse, France; CNRS; ITAV-USR3505, F-31106 Toulouse, France.
Marie-Laure BoizeauUniversité de Toulouse; ITAV-USR3505, F-31106 Toulouse, France; CNRS; ITAV-USR3505, F-31106 Toulouse, France.
Valérie LobjoisUniversité de Toulouse; ITAV-USR3505, F-31106 Toulouse, France; CNRS; ITAV-USR3505, F-31106 Toulouse, France.
Bernard DucommunUniversité de Toulouse; ITAV-USR3505, F-31106 Toulouse, France; CNRS; ITAV-USR3505, F-31106 Toulouse, France; CHU de Toulouse; F-31059 Toulouse, France.
Université de Toulouse · FRInstitut des Technologies Avancées en sciences du Vivant · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monitoring the DNA-Damage Response (DDR) activated pathway in multicellular tumor spheroid models is an important challenge as these 3D models have demonstrated their major relevance in pharmacological evaluation. Herein we present DDR-Act-FP, a fluorescent biosensor that allows detection of DDR activation through monitoring of the p21 promoter p53-dependent activation. We show that cells expressing the DDR-Act-FP biosensor efficiently report activation of the DDR pathway after DNA damage and its pharmacological manipulation using ATM kinase inhibitors. We also report the successful use of this assay to screen a small compound library in order to identify activators of the DDR response. Finally, using multicellular spheroids expressing the DDR-Act-FP we demonstrate that DDR activation and its pharmacological manipulation with inhibitory and activatory compounds can be efficiently monitored in live 3D spheroid model. This study paves the way for the development of innovative screening and preclinical evaluation assays.

Indexed as

DNA DamageModels, BiologicalHEK293 CellsHumans

Identifiers

PMID26225756
PMCPMC4520595
OpenAlexW1899329298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.